The Biosecure Act is moving forward after being approved by the U.S. House as part of the National Defense Authorization Act. This law is expected to be passed by the Senate and signed by the president soon. The main goal of the Biosecure Act is to pressure companies to cut ties with certain Chinese firms to protect national security. The latest version of the law is less strict than initially proposed but still aims to prevent U.S. federal money from going to risky foreign biotech companies. It also includes changes to protect companies from unintended penalties. The law now uses a list from the Department of Defense to identify concerning biotech companies instead of naming specific firms. This change was made to avoid violating due process rights. Federal agencies and recipients of grants or loans cannot use equipment and services from these listed companies. The compliance timelines have also been adjusted, with some companies getting a roughly five-year period to wind down existing contracts. There is also more flexibility for U.S. companies buying equipment from China, with some specific items no longer explicitly mentioned. The new law includes clearer waivers and protections to avoid disrupting federal health programs. However, the pharmaceutical industry faces challenges in breaking ties with Chinese biotech companies, which make up a significant portion of global manufacturers. Some companies are looking to source ingredients from other countries or bring production back to the U.S. As the Biosecure Act advances, pharma companies need to understand their manufacturing processes and track changes to the law. The industry must balance collaboration with China for drug development while protecting national security.